Current Problems in Cardiology
Volume 33, Issue 12 , Pages 703-768 , December 2008

Adverse Drug Reactions in Patients with Cardiovascular Disease

References 

  1. International drug monitoring: the role of national centres (Report of a WHO meeting). World Health Organ Tech Rep Ser. 1972;498:1–25
  2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205
  3. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998;316(7140):1295–1298
  4. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995;155(18):1949–1956
  5. Woosley RL. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J. 1987;114(5):1280–1291
  6. Stolarek I, Scott PJ, Caird FI. Physiological changes due to age: implications for cardiovascular drug therapy. Drugs Aging. 1991;1(6):467–476
  7. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38(11):504–513
  8. Landi F, Gambassi G, Lapane KL, et al. Comorbidity and drug use in cognitively impaired elderly living in long-term care. Dement Geriatr Cogn Disord. 1998;9(6):347–356
  9. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In:  Davies DM editors. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press; 1981;
  10. Hebbard GS, Sun WM, Bochner F, Horowitz M. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin Pharmacokinet. 1995;28(1):41–66
  11. Greiff JM, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet. 1994;27(6):447–467
  12. McElnay JC, Harron DW, D'Arcy PF, Eagle MR. Interaction of digoxin with activated dimethicone and other antacid constituents. Experientia. 1979;35(1):94
  13. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S. Modulators of the multidrug-transporter, P-glycoprotein, exist in the human plasma. Biochem Biophys Res Commun. 1990;166(1):74–80
  14. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78(3):260–277
  15. Funakoshi S, Murakami T, Yumoto R, Kiribayashi Y, Takano M. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci. 2005;94(6):1196–1203
  16. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18(1):84–112
  17. Salem SA, Rajjayabun P, Shepherd AM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Ageing. 1978;7(2):68–73
  18. Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin. 2001;19(2):215–234
  19. Gunstone RF, Wing AJ, Shani HJ, Njemo D, Sabuka EM. Clinical experience with metolazone in fifty-two African patients: synergy with frusemide. Postgrad Med J. 1971;47(554):789–793
  20. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000;11(6):691–696
  21. Jia H, Hingorani AD, Sharma P, et al. Association of the G(s) alpha gene with essential hypertension and response to beta-blockade. Hypertension. 1999;34(1):8–14
  22. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74(1):44–52
  23. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13(5):247–252
  24. Johnson JA, Cavallari LH. Cardiovascular pharmacogenomics. Exp Physiol. 2005;90(3):283–289
  25. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64(5):477–483
  26. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine—and its potential clinical relevance. Eur J Clin Pharmacol. 1992;42(3):313–317
  27. Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med. 2002;8(3):293–308
  28. Aggarwal A, Ades PA. Interactions of herbal remedies with prescription cardiovascular medications. Coron Artery Dis. 2001;12(7):581–584
  29. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66(4):338–345
  30. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;355(9203):548–549
  31. Olukoga A, Donaldson D. Liquorice and its health implications. J R Soc Health. 2000;120(2):83–89
  32. Sear JW, Higham H. Issues in the perioperative management of the elderly patient with cardiovascular disease. Drugs Aging. 2002;19(6):429–451
  33. Vestal RE, Wood AJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979;26(2):181–186
  34. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics. 2000;10(1):5–10
  35. Harder S, Klinkhardt U. Thrombolytics: drug interactions of clinical significance. Drug Saf. 2000;23(5):391–399
  36. Romeo F, Rosano GM, Martuscelli E, et al. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J. 1995;130(4):692–697
  37. Gusto IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes (The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators). Circulation. 1994;90(4):1631–1637
  38. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(9):e82–e292
  39. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction (ISIS-3 (Third International Study of Infarct Survival) Collaborative Group). Lancet. 1992;339(8796):753–770
  40. Gibson CM. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med. 1999;130(10):841–847
  41. Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?. Pharmacotherapy. 1998;18(5):1041–1052
  42. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95(4):509–510
  43. Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med. 1977;296(10):525–529
  44. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100(15):1667–1672
  45. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol. 2003;41(suppl 4):79S–88S
  46. Dunlop H, Siu K. Serious hematologic reactions associated with ticlopidine–update. CMAJ. 1999;161(7):867–868
  47. Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6):563–568
  48. McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother. 2003;37(2):216–219
  49. Lutsep HL. MATCH results: implications for the internist. Am J Med. 2006;119(6):526;e1-7
  50. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?. Eur Heart J. 2005;26(6):576–583
  51. Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and Clopidogrel resistance. Mayo Clin Proc. 2006;81(4):518–526
  52. Biaggioni I, Onrot J, Hollister AS, et al. Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole. Life Sci. 1986;39(23):2229–2236
  53. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med. 2002;30(suppl 5):S332–S340
  54. Mascelli MA, Damaraju L, Wagner CL, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97(17):1680–1688
  55. Collet JP, Montalescot G, Lesty C, et al. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001;103(19):2328–2331
  56. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357(9272):1915–1924
  57. Morrow DA, Sabatine MS, Antman EM, et al. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004;94(6):774–776
  58. Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41(3):187–195
  59. The Pursuit Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy). N Engl J Med. 1998;339(7):436–443
  60. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–1887
  61. Luskin AT, Luskin SS. Anaphylaxis and anaphylactoid reactions: diagnosis and management. Am J Ther. 1996;3(7):515–520
  62. Delaney A, Carter A, Fisher M. The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review. BMC Med Imaging. 2006;6:2
  63. Oliveira Neto AM, Duare NM, Vicente WV, et al. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit. 2003;9(11):CS102-6
  64. Tadros GM, Mouhayar EM, Akinwande AO, et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol. 2003;15(6):311–314
  65. Isenbarger DW, Resar JR. Drug-eluting versus third-generation bare metal stents: the US strategy. Int J Cardiovasc Intervent. 2005;7(4):171–175
  66. Wessely R, Schomig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47(4):708–714
  67. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175–181
  68. Feres F, Costa JR, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006;68(1):83–88
  69. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49(6):734–739
  70. Rasuli P, Hammond DI. Metformin and contrast media: where is the conflict?. Can Assoc Radiol J. 1998;49(3):161–166
  71. Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther. 2004;9(suppl 1):S85–S97
  72. Croft JB, Giles WH, Pollard RA, et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999;159(5):505–510
  73. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (Randomized Aldactone Evaluation Study Investigators). N Engl J Med. 1999;341(10):709–717
  74. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Investigators (Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction). N Engl J Med. 2003;348(14):v1309–v1321
  75. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–551
  76. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–771
  77. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13
  78. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199
  79. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) (MERIT-HF Study Group). JAMA. 2000;283(10):1295–1302
  80. Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med. 1992;92(5):527–538
  81. Waagstein F. Beta blockers in heart failure. Cardiology. 1993;82(suppl 3):13–18
  82. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure (The SOLVD Investigators). N Engl J Med. 1991;325(5):293–302
  83. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group). N Engl J Med. 1987;316(23):1429–1435
  84. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail. 2005;7(5):710–721
  85. Silver PJ, Harris AL, Canniff PC, et al. Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J Cardiovasc Pharmacol. 1989;13(4):530–540
  86. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure (The PROMISE Study Research Group). N Engl J Med. 1991;325(21):1468–1475
  87. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 Pt. 1):78–86
  88. El-Sayed , Abdelfattah RR, Barcelona R, Leier CV. Dobutamine-induced eosinophilia. Am J Cardiol. 2004;93(8):1078–1079
  89. Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497–504
  90. Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments Final report of a multicenter study. Circulation. 1990;81(6):1744–1752
  91. Alam AN, Saha JR, Dobkin JF, et al. Interethnic variation in the metabolic inactivation of digoxin by the gut flora. Gastroenterology. 1988;95(1):117–123
  92. Pedersen KE. Digoxin interactions (The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides). Acta Med Scand Suppl. 1985;697:1–40
  93. Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol. 1998;38(7):654–657
  94. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111(12):1487–1491
  95. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson KD. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900–1905
  96. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Lancet. 2000;355(9207):863–864
  97. Kotchen TA, Zhang HY, Reddy S, et al. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol. 1996;270(3 Pt. 2):R660–R666
  98. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–2064
  99. Giles TD. The patient with diabetes mellitus and heart failure: at-risk issues. Am J Med. 2003;115(suppl 8A):107S–110S
  100. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134(1):61–71
  101. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 1999;33(7):1920–1925
  102. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79(2):115–119
  103. Massie BM. Aspirin use in chronic heart failure: what should we recommend to the practitioner?. J Am Coll Cardiol. 2005;46(6):963–966
  104. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10(2):101–112
  105. Yusuf S, Theodoropoulos S, Mathias CJ, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. Circulation. 1987;75(4):696–704
  106. Ellenbogen KA, Szentpetery S, Katz MR. Reversibility of prolonged chronotropic dysfunction with theophylline following orthotopic cardiac transplantation. Am Heart J. 1988;116(1 Pt. 1):202–206
  107. Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart (Evidence of supersensitivity). Circulation. 1990;81(3):821–828
  108. Wagoner LE. Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Am J Med Sci. 1997;314(3):173–184
  109. Schroeder JS, Gao JS, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328(3):164–170
  110. Page RL, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005;39(6):1109–1113
  111. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–564
  112. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62(3):311–321
  113. Page RL, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation. 2005;111(2):230–239
  114. Zetia [package insert]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2003;
  115. Kunicki PK, Sobieszczanska-Malek M. Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. Ther Drug Monit. 2005;27(1):107–108
  116. Federico S, Carrano R, Capone D, et al. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006;45(2):169–175
  117. Bottiger Y, Säwe J, Brattström C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther. 2001;69(1):32–40
  118. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22(suppl B):B101–B121
  119. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002;42(2):222–228
  120. Kaplan B, Meier-Kriesche HU, Napoli KL, et al. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther. 1998;63(1):48–53
  121. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(suppl 2):S244–S253
  122. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28(2):925–929
  123. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30(9):951–954
  124. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health. 2006;27:465–490
  125. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
  126. Amar J, Vaur L, Perret M, et al. Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J Hypertens. 2002;20(4):779–784
  127. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). JAMA. 2002;288(23):2981–2997
  128. Opie LH. Diuretic downsides—but in low doses they still seem among the best authenticated antihypertensives. Cardiovasc Drugs Ther. 2000;14(4):407–409
  129. Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10–24
  130. Stamp L, Searle M, O'Donnell J, et al. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593–2611
  131. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991;90(5A):42S–47S
  132. Mignat C, Unger T. ACE inhibitors (Drug interactions of clinical significance). Drug Saf. 1995;12(5):334–347
  133. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, et al. Magnesium and cardiovascular drugs: interactions and therapeutic role. Ann Ital Med Int. 1999;14(1):40–45
  134. Spiers DR, Wade RC. Double-blind parallel study of a combination of chlorthalidone 50 mg and triamterene 50 mg in patients with mild and moderate hypertension. Curr Med Res Opin. 1996;13(7):409–415
  135. Fujii H, Nakahama H, Yoshihara F, et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. Kobe J Med Sci. 2005;51(1-2):1–6
  136. Wiesfeld AC, Remme WJ, Look MP, et al. Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol. Am J Cardiol. 1992;70(11):997–1003
  137. Bailey DG, Carruthers SG. Interaction between oral verapamil and beta-blockers during submaximal exercise: relevance of ancillary properties. Clin Pharmacol Ther. 1991;49(4):370–376
  138. Boutitie F, Boisell JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases (The EMIAT and CAMIAT Investigators). Circulation. 1999;99(17):2268–2275
  139. Cummings DM, Vlasses PH. Antihypertensive drug withdrawal syndrome. Drug Intell Clin Pharm. 1982;16(11):817–822
  140. Nies AS, Shand DG. Hypertensive response to propranolol in a patient treated with methyldopa—a proposed mechanism. Clin Pharmacol Ther. 1973;14(5):823–826
  141. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345(5):351–358
  142. Ormiston TM, Salpeter SR. Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail Monit. 2003;4(2):45–54
  143. Webster J. Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications. Drugs. 1985;30(1):32–41
  144. Conrad KA, Byers JM, Finley PR, et al. Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther. 1983;33(2):133–138
  145. Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem. 1990;8(suppl 2):28–34
  146. McLean AJ, Knight R, Harrison PM, et al. Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol. Am J Cardiol. 1985;55(13 Pt. 1):1628–1629
  147. Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol. 2001;38(5):1295–1296
  148. Sica DA. Doxazosin and congestive heart failure. Congest Heart Fail. 2002;8(3):178–184
  149. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M–46M
  150. Lenz ML, Pool JL, Laddu AR, et al. Combined terazosin and verapamil therapy in essential hypertension Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995;8(2):133–145
  151. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447–1457
  152. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337(8736):268–269
  153. Opie LH. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease. Cardiovasc Drugs Ther. 1996;10(4):455–461
  154. Holtzman JL, FInley D, Mottonen L, et al. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther. 1989;46(1):26–32
  155. Lesko LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet. 1989;17(2):130–140
  156. Jaffe R, Livshits T, Bursztyn M. Adverse interaction between clonidine and verapamil. Ann Pharmacother. 1994;28(7-8):881–883
  157. Doppenschmitt S, Langguth P, Regardh CG, et al. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999;288(1):348–357
  158. Sokol SI, Cheng A, Frishman WH, et al. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol. 2000;40(1):11–30
  159. Verschraagen M, Koks CH, Schellens JH, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res. 1999;40(4):301–306
  160. Gordon M, Goldenberg LM. Clinical digoxin toxicity in the aged in association with co-administered verapamil (A report of two cases and review of the literature). J Am Geriatr Soc. 1986;34(9):659–662
  161. Rosenthal T, Ezra D. Calcium antagonists (Drug interactions of clinical significance). Drug Saf. 1995;13(3):157–187
  162. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 suppl 1):III50–III57
  163. Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens. 2003;21(10):969–973
  164. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens. 2001;14(9 Pt. 1):963–968
  165. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(suppl 1):169S–173S
  166. Fox AJ, Lalloo UG, Belvisi MG, et al. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med. 1996;2(7):814–817
  167. Fuchs SA, Meyboom RH, van Puijenbroek EP, et al. Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. Pharm World Sci. 2004;26(4):191–192
  168. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–776
  169. Finley PR, O'Brien JG, Coleman RW. Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol. 1996;16(1):68–71
  170. Conlin PR, Moore TJ, Schwartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36(3):461–465
  171. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med. 2001;94(10):512–514
  172. Mazurek W, Haczynski J. [Interaction of captopril and digoxin]. Pol Tyg Lek. 1993;48(50-52):834–835
  173. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf. 2003;26(10):707–720
  174. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997;62(3):272–278
  175. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(suppl 1):S73–S86
  176. McClellan KJ, Goa KL. Candesartan cilexetil (A review of its use in essential hypertension). Drugs. 1998;56(5):847–869
  177. Stangier J, Su CA, Hendricks MG, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1373–1379
  178. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44–48
  179. Price EJ, Venables PJ. Drug-induced lupus. Drug Saf. 1995;12(4):283–290
  180. Schneck DW, Vary JE. Mechanism by which hydralazine increases propranolol bioavailability. Clin Pharmacol Ther. 1984;35(4):447–453
  181. Miller DD, Love DW. Evaluation of minoxidil. Am J Hosp Pharm. 1980;37(6):808–814
  182. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24(4):129–147
  183. Fichtl B, Doering W. The quinidine-digoxin interaction in perspective. Clin Pharmacokinet. 1983;8(2):137–154
  184. Sindrup SH, Arendt-Nielsen L, Brosen K, et al. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol. 1992;42(6):587–591
  185. Ellenbogen KA, Wood MA, Stambler BS. Procainamide: a perspective on its value and danger. Heart Dis Stroke. 1993;2(6):473–476
  186. Danielly J, DeJong R, Radke-Mitchell LC, et al. Procainamide-associated blood dyscrasias. Am J Cardiol. 1994;74(11):1179–1180
  187. Vlasses PH, Kosoglou T, Chase SL, et al. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Arch Intern Med. 1989;149(6):1350–1353
  188. Martin DE, Shen J, Griener J, et al. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol. 1996;36(1):85–91
  189. Bonde J, Bodtker S, Angelo HR, et al. Atenolol inhibits the elimination of disopyramide. Eur J Clin Pharmacol. 1985;28(1):41–43
  190. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med. 1989;86(4):465–466
  191. Siegmund JB, Wilson JH, Imhoff TE. Amiodarone interaction with lidocaine. J Cardiovasc Pharmacol. 1993;21(4):513–515
  192. Pentikainen PJ, Koivula IH, Hiltunen HA. Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol. 1982;23(3):261–266
  193. Begg EJ, Chinwah PM, Webb C, et al. Enhanced metabolism of mexiletine after phenytoin administration. Br J Clin Pharmacol. 1982;14(2):219–223
  194. Hurwitz A, Vacek JL, Botteron GW, et al. Mexiletine effects on theophylline disposition. Clin Pharmacol Ther. 1991;50(3):299–307
  195. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311–320
  196. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction (The Cardiac Arrhythmia Suppression Trial (CAST) Investigators). N Engl J Med. 1989;321(6):406–412
  197. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther. 1994;55(3):256–269
  198. Nolan PE, Marcus FI, Erstad BL, et al. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. J Clin Pharmacol. 1989;29(1):46–52
  199. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. 2000;23(6):509–532
  200. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther. 1987;42(3):305–311
  201. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial CAST Investigators. Am J Cardiol. 1994;74(7):674–680
  202. Ogunyankin KO, Singh BN. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Cardiol. 1999;84(9A):76R–82R
  203. Blitzer M, Costeas C, Kassotis J, et al. Rhythm management in atrial fibrillation—with a primary emphasis on pharmacological therapy: Part 1. Pacing Clin Electrophysiol. 1998;21(3):590–602
  204. Thomas M, Maconochie MG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol. 1996;41(2):77–81
  205. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9(2):136–156
  206. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999;84(9A):37R–45R
  207. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone (Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology). Arch Intern Med. 2000;160(12):1741–1748
  208. Lee KL, Tai YT. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Clin Cardiol. 1997;20(4):372–377
  209. Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in patients with heart failure (The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320)). J Am Coll Cardiol. 1997;30(2):514–517
  210. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82(1):51–59
  211. Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med. 1989;86(1):4–10
  212. Jessurun GA, Boersma WG, Crijns HJ. Amiodarone-induced pulmonary toxicity (Predisposing factors, clinical symptoms and treatment). Drug Saf. 1998;18(5):339–344
  213. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679–685
  214. Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother. 1995;29(6):582–586
  215. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791–798
  216. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507–511
  217. Roti E, Minelli R, Gardini E, et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone A possible consequence of a destructive process in the thyroid. Arch Intern Med. 1993;153(7):886–892
  218. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989;35(9):1882–1887
  219. Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. 1998;8(1):83–100
  220. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987;26(1-4):158–171
  221. Broussolle C, Ducottet X, Martin C, et al. Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis (Comparison of two groups of patients with apparently normal thyroid glands). J Endocrinol Invest. 1989;12(1):37–42
  222. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981;99(2):257–261
  223. Blackshear JL, Randle HW. Reversibility of blue-gray cutaneous discoloration from amiodarone. Mayo Clin Proc. 1991;66(7):721–726
  224. Nicolau DP, Uber WE, Crumbley AJ, et al. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant. 1992;11(3 Pt 1):564–568
  225. Matheny CJ, Lamb MW, Brouwer KR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 2001;21(7):778–796
  226. Yamreudeewong W, DeBisschop M, Martin LG, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421–438
  227. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med. 1988;148(8):1779–1781
  228. Leor J, Levartowsky D, Sharon C, et al. Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J. 1988;116(1 Pt 1):206–207
  229. Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J. 1985;109(1):163–164
  230. Product Information (Tikosyn [(TM)] dofetilide). New York, NY: Pfizer; 1999;
  231. Freeland S, Worthy C, Zolnierz M. Initiation and monitoring of class III antiarrhythmic agents. J Cardiovasc Electrophysiol. 2003;14(suppl 12):S291–S295
  232. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy. 1997;17(1):1–9
  233. Seideman P, Grahnen A, Haglund K, et al. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol. 1982;13(6):865–870
  234. Saarimaa H. Combination of clonidine and sotalol in hypertension. Br Med J. 1976;810:1;(6013)
  235. Laer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol. 1997;43(3):269–272
  236. McCabe JL, Adhar GC, Menegazzi JJ, et al. Intravenous adenosine in the prehospital treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1992;21(4):358–361
  237. von der Leyen H. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure. Klin Wochenschr. 1989;67(12):605–615
  238. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol. 2003;10(suppl 1):2–6
  239. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37(suppl 2):61–68
  240. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37(suppl 2):53–59
  241. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3(2):117–138
  242. Tjon JA, Riemann LE. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Syst Pharm. 2001;58(6):485–493quiz 494-6
  243. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone. 2005;7(1):47–56
  244. Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83(5A):21C–28C
  245. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23(3):197–213
  246. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85(12A):15E–19E
  247. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89(12):1374–1380
  248. Flint OP, Masters BA, Gregg RE, et al. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145(1):99–110
  249. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57(1):62–66
  250. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother. 2006;40(2):290–294
  251. Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004;148(2):200–210
  252. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999;84(7):811–815
  253. Altmann SW, Davis HR, Zhu LJ. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–1204
  254. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–494
  255. Bergman AJ, Burke J, Larson P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006;46(3):321–327
  256. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 1997;12(10):591–596
  257. McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271(9):672–677
  258. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28(3):263–275
  259. Balfour JA, McTavish D, Heel RC. Fenofibrate (A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia). Drugs. 1990;40(2):260–290
  260. Serrano G, Fortea JM, Latasa JM, et al. Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. J Am Acad Dermatol. 1992;27(2 Pt. 1):204–208
  261. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106
  262. Brown RA, Larkin JC, Davis RL. Current concepts in the management of smoking cessation: a review. Am J Manag Care. 2000;6(3):394–401quiz 402-4
  263. Homsy W, Yan K, Houle JM, et al. Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. J Clin Pharmacol. 1997;37(8):728–736
  264. Houston TP, Elster AB, Davis RM, et al. The U.S. Preventive Services Task Force Guide to Clinical Preventive Services, Second Edition AMA Council on Scientific Affairs. Am J Prev Med. 1998;14(4):374–376
  265. Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA. 1999;281(1):72–76
  266. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28(10):1176–1183
  267. Ross S, Williams D. Bupropion: risks and benefits. Exp Opin Drug Saf. 2005;4(6):995–1003
  268. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55
  269. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30(3):273–283
  270. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136(3):210–215
  271. Heit JA. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res. 2001;101(1):V163–V173
  272. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J. 2004;25(19):1688–1694
  273. Fitchett DH, Langer A, Armstrong PW, et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J. 2006;151(2):373–379
  274. de Maistre E, Allart C, Lecompte T, et al. Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors. Am J Med. 2002;113(6):530–532
  275. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43(5):453–462
  276. Ramakrishna R, Manoharan A, Kwan YL, et al. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol. 1995;91(3):736–738
  277. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22(6 Pt. 2):105S–111S
  278. Chew DP, Bhatt DL, Kimball W. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92(8):919–923
  279. Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47(4):804–808
  280. Haimovici H. The ischemic forms of venous thrombosis. 1 (Phlegmasia cerulea dolens. 2. Venous gangrene). J Cardiovasc Surg (Torino). 1965;(Suppl):164–173
  281. Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19(7):902–908
  282. Barry PJ, O'Keefe N, O'Connor KA, et al. Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther. 2006;31(6):617–626

 The authors have no conflicts of interest or relationships to disclose.

PII: S0146-2806(08)00125-4

doi: 10.1016/j.cpcardiol.2008.08.002

Current Problems in Cardiology
Volume 33, Issue 12 , Pages 703-768 , December 2008

Article Tools

* Image Usage & Resolution